triciribine phosphate + paclitaxel + doxorubicin + cyclophosphamide

This is an **investigational combination regimen** consisting of **triciribine phosphate (TCN-P or PTX-200)**, **paclitaxel**, **doxorubicin**, and **cyclophosphamide**. Triciribine phosphate is a small-molecule prodrug that inhibits all three isoforms of **AKT**, a serine/threonine kinase critical in the PI3K/AKT pathway involved in cell proliferation and survival[2][4]. Paclitaxel is a microtubule-stabilizing agent, doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, and cyclophosphamide is an alkylating agent[3]. This combination is under investigation for the treatment of **stage IIB-IV breast cancer**, with the hypothesis that targeting AKT alongside traditional cytotoxics may provide additive or synergistic anticancer effects[3].

Other names

TCN-PMtriciribine phosphate monohydrate